Accessibility Menu
Advanced Biomed logo

Advanced Biomed(NASDAQ) ADVB

Market Cap$23.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-80%
5 YearN/A
1 Year+44%
1 Month+220%
$9.99
-30.43%
-4.37Today
Advanced Biomed last closing stock price
MetricPriceDate
Last closeUSD 14.362026-07-27
Advanced Biomed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+61.35%USD 8.902026-07-20
1 month+219.82%USD 4.492026-06-26
3 month+170.94%USD 5.302026-04-28
Year to date+146.06%USD 5.842025-12-31
1 year+43.66%USD 10.002025-07-25
Since inception-80.33%USD 73.002025-03-06

Advanced Biomed Financials at a Glance

Market Cap

$23.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$677.61K

EPS (TTM)

$0.16

P/E Ratio

90.20

Dividend

$0.00

Beta (Volatility)

0.05 (Low)

Price

$9.99

Volume

253,242.971

Open

$12.07

Previous Close

$10.88

Daily Range

$9.49 - $12.60

52-Week Range

$3.61 - $24.23

Estimated Earnings Date

May 15, 2025

ADVB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Advanced Biomed

Advanced Biomed develops devices that help doctors detect and analyze cancer cells. Its products support early cancer diagnosis and treatment planning for patients and clinics. The company’s technology aims to make cancer testing more precise and accessible.

Gadgets That Spot Trouble: Products and Services

  • Microfluidic Devices: Tools for isolating and analyzing rare cancer cells in blood; no revenue yet.
  • Sample Preparation Systems: Machines that prepare blood samples for cancer testing; no revenue contribution reported.
  • Immunochromogenic Kits: Kits that identify different types of tumor cells using antibodies; no sales to date.
  • Early Cancer Screening: Lung cancer screening kit in development; not yet generating revenue.
  • Medical Clinics: Operates clinics in China offering cancer testing services; no revenue reported.

Growth Spurts and Global Hops

  • Completed IPO in March 2025, raising $6.56 million in gross proceeds before deducting underwriting discounts or expenses for expansion.
  • Received product clearance from China’s NMPA for A+Pre and AC-1000.
  • Started regulatory applications for new products and kits in China.
  • Plans to launch clinical research for lung cancer screening in 2025–2026.
  • Preparing to enter US and European markets with local subsidiaries.

What Makes Advanced Biomed Stand Out

Advanced Biomed combines semiconductor and biotechnology to create modular cancer testing devices. Its products are designed for use with both in-house and third-party lab tools. The company focuses on adapting its technology for different regulatory markets and local needs.

Five Things You Need to Know

  • Revenue was $0 in Q1 2026, unchanged from Q1 2025 and Q1 2024.
  • Net loss was $-1,603 in Q1 2026, improving 49.3% from Q1 2025.
  • Cash was $10 million in Q1 2026, down 86.7% from Q1 2025.
  • Operating loss was $-17,503 in Q1 2026, down 8.8% from Q1 2025.
  • Company relies on IPO funds and related party loans for operations.

Bottom Line

Advanced Biomed is an early-stage company focused on cancer diagnostics technology. It remains in development, with no product sales and ongoing operating losses as of Q1 2026.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

31

CEO

Yi Lu, PhD

Website

www.advanbiomed.com

Headquarters

New York City, NY 10168, US

ADVB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-20.71%

Return on Capital

-1.98%

Return on Assets

-6.36%

Earnings Yield

1.11%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$23.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.65M

Volume

253.24K

Avg. Volume

1.80M

Financials (TTM)

Gross Profit

-$2.84K

Operating Income

-$1.10M

EBITDA

-$1.00M

Operating Cash Flow

-$691.70K

Capital Expenditure

-$2.90K

Free Cash Flow

-$694.59K

Cash & ST Invst.

$2.60M

Total Debt

$712.53K

Advanced Biomed Performance Analysis

Advanced Biomed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 0N/A
20232023-06-30USD 0N/A
20242024-06-30USD 0N/A
20252025-06-30USD 0N/A
Advanced Biomed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30N/A
Q12025-09-30N/A
Q22025-12-31N/A
Q32026-03-31N/A
Advanced Biomed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -0.13N/A
20232023-06-30USD -0.11-14.7%
20242024-06-30USD -0.08-28.0%
20252025-06-30USD -0.0916.1%
Advanced Biomed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-3041.0%
Q12025-09-3042.9%
Q22025-12-311766.7%
Q32026-03-31-290.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$294.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$23.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$765.31K

N/A

Employees

31

N/A

Net Income

-$488.94K

+64.7%

EBITDA

-$479.50K

+9.3%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$2.60M

+1567.0%

Total Debt

$712.53K

+281.0%

Accounts Receivable

$3.02K

-53.3%

Inventory

$0.00

N/A

Long Term Debt

$10.90K

-75.5%

Short Term Debt

$701.63K

+392.3%

Return on Assets

-6.36%

N/A

Return on Invested Capital

-11.88%

N/A

Free Cash Flow

-$6.93K

+99.8%

Operating Cash Flow

-$6.90K

+99.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRKRMarker Therapeutics, Inc.
$1.18-3.28%
CHEKCheck-Cap Ltd.
$1.86+1.64%
APMAptorum Group Limited
$8.99-5.77%
GELSGelteq Limited Ordinary Shares
$0.59-11.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$197.01+0.00%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.22-0.01%
NOKNokia
$8.93-0.03%
JBLUJetBlue Airways
$6.00+0.10%

Questions About ADVB

What is the current price of Advanced Biomed?

Advanced Biomed is trading at $10.88 per share.

What is the 52-week range for Advanced Biomed?

Over the past 52 weeks, Advanced Biomed has traded between $3.61 and $24.23.

How much debt does Advanced Biomed have?

As of the most recent reporting period, Advanced Biomed reported total debt of $23.21K.

How much cash does Advanced Biomed have on hand?

Advanced Biomed reported $81.41K in cash and cash equivalents in its most recent financial results.

What is Advanced Biomed’s dividend yield?

Advanced Biomed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services